Previous Close | 45.82 |
Open | 45.75 |
Bid | 45.33 x 1000 |
Ask | 45.37 x 800 |
Day's Range | 45.07 - 46.16 |
52 Week Range | 34.00 - 63.00 |
Volume | |
Avg. Volume | 1,069,823 |
Market Cap | 5.429B |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.49 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 74.14 |
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
AUSTIN, Texas, September 18, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
An in-depth look at Natera Inc's valuation and financial performance
AUSTIN, Texas, September 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes.